INT Medical Plans Governance Overhaul: Articles of Association to be Amended, Supervisory Committee to Be Abolished

Bulletin Express03-27

Shanghai INT Medical Instruments Co., Ltd. (INT Medical, 01501) disclosed that its Board resolved on 27 March 2026 to initiate two major corporate-governance changes. First, selected provisions of the Articles of Association will be revised to align with the Company Law of the PRC, the Guidelines on Articles of Association of Listed Companies and Hong Kong Listing Rules. Second, the existing Supervisory Committee will be abolished, with its oversight functions migrating to the Board’s Audit Committee.

The proposals require approval by special resolutions at the forthcoming annual general meeting. A circular detailing the amendments and meeting arrangements will be posted on the HKEX website and the company’s portal (www.int-medical.com) before dispatch to shareholders.

As of the announcement date, INT Medical’s Board consists of two executive directors (Dr. Liang Dongke, Mr. Lin Sen), four non-executive directors (Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin, Mr. Zhang Hong) and three independent non-executive directors (Mr. Jian Xigao, Mr. Hui Hung Kwan, Mr. Xu Congli). Dr. Liang Dongke serves as Board Chairman.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111373571?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111373571","market":"hk","top_or_hot":-1,"title":"INT Medical Plans Governance Overhaul: Articles of Association to be Amended, Supervisory Committee to Be Abolished","media":"Bulletin Express","content":"<p>Shanghai INT Medical Instruments Co., Ltd. (INT Medical, 01501) disclosed that its Board resolved on 27 March 2026 to initiate two major corporate-governance changes. First, selected provisions of the Articles of Association will be revised to align with the Company Law of the PRC, the Guidelines on Articles of Association of Listed Companies and Hong Kong Listing Rules. Second, the existing Supervisory Committee will be abolished, with its oversight functions migrating to the Board’s Audit Committee.</p>\n<p>The proposals require approval by special resolutions at the forthcoming annual general meeting. A circular detailing the amendments and meeting arrangements will be posted on the HKEX website and the company’s portal (www.int-medical.com) before dispatch to shareholders.</p>\n<p>As of the announcement date, INT Medical’s Board consists of two executive directors (Dr. Liang Dongke, Mr. Lin Sen), four non-executive directors (Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin, Mr. Zhang Hong) and three independent non-executive directors (Mr. Jian Xigao, Mr. Hui Hung Kwan, Mr. Xu Congli). Dr. Liang Dongke serves as Board Chairman.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INT Medical Plans Governance Overhaul: Articles of Association to be Amended, Supervisory Committee to Be Abolished</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINT Medical Plans Governance Overhaul: Articles of Association to be Amended, Supervisory Committee to Be Abolished\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-27 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai INT Medical Instruments Co., Ltd. (INT Medical, 01501) disclosed that its Board resolved on 27 March 2026 to initiate two major corporate-governance changes. First, selected provisions of the Articles of Association will be revised to align with the Company Law of the PRC, the Guidelines on Articles of Association of Listed Companies and Hong Kong Listing Rules. Second, the existing Supervisory Committee will be abolished, with its oversight functions migrating to the Board’s Audit Committee.</p>\n<p>The proposals require approval by special resolutions at the forthcoming annual general meeting. A circular detailing the amendments and meeting arrangements will be posted on the HKEX website and the company’s portal (www.int-medical.com) before dispatch to shareholders.</p>\n<p>As of the announcement date, INT Medical’s Board consists of two executive directors (Dr. Liang Dongke, Mr. Lin Sen), four non-executive directors (Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin, Mr. Zhang Hong) and three independent non-executive directors (Mr. Jian Xigao, Mr. Hui Hung Kwan, Mr. Xu Congli). Dr. Liang Dongke serves as Board Chairman.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01501","symbol_name":"瑛泰医疗","start_time":0,"source_url":"","article_id":"1111373571","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111373571","pubTimestamp":1774612011,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai INT Medical Instruments Co., Ltd. (INT Medical, 01501) disclosed that its Board resolved on 27 March 2026 to initiate two major corporate-governance changes. First, selected provisions of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01501":"瑛泰医疗"},"translate_title":"INT Medical Plans治理改革：修改公司章程，撤销监事会","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01501":1},"content_text":"Shanghai INT Medical Instruments Co., Ltd. (INT Medical, 01501) disclosed that its Board resolved on 27 March 2026 to initiate two major corporate-governance changes. First, selected provisions of the Articles of Association will be revised to align with the Company Law of the PRC, the Guidelines on Articles of Association of Listed Companies and Hong Kong Listing Rules. Second, the existing Supervisory Committee will be abolished, with its oversight functions migrating to the Board’s Audit Committee.\nThe proposals require approval by special resolutions at the forthcoming annual general meeting. A circular detailing the amendments and meeting arrangements will be posted on the HKEX website and the company’s portal (www.int-medical.com) before dispatch to shareholders.\nAs of the announcement date, INT Medical’s Board consists of two executive directors (Dr. Liang Dongke, Mr. Lin Sen), four non-executive directors (Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin, Mr. Zhang Hong) and three independent non-executive directors (Mr. Jian Xigao, Mr. Hui Hung Kwan, Mr. Xu Congli). Dr. Liang Dongke serves as Board Chairman.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111373571","isCrawlerRequest":true}